Do Wall Street Analysts Like Incyte Corporation Stock?

Headquartered in Wilmington, Delaware, Incyte Corporation (INCY) discovers, develops, and commercializes innovative therapies that confront some of medicine’s toughest challenges. Commanding a market cap of roughly $19.6 billion, the company targets blood cancers, solid tumors, immune-mediated disorders, and dermatological diseases.

Over the past 52 weeks, INCY stock has surged 49%, comfortably eclipsing the S&P 500 Index ($SPX) 14.4% gain during the same period. Year-to-date (YTD), INCY stock remains marginally positive, while the broader index has gained 1.4%.